Phase 2 study of tebapivat in in sickle cell disease
Latest Information Update: 20 Jan 2025
Price :
$35 *
At a glance
- Drugs Tebapivat (Primary)
- Indications Sickle cell anaemia
- Focus Therapeutic Use
- 20 Jan 2025 New trial record
- 13 Jan 2025 According to Agios Pharmaceuticals media release, company to begin patient enrollment for this Phase 2 study of tebapivatin in sickle cell disease in mid-2025.